熱門資訊> 正文

I-Mab Bizerma GAAP每股收益为-0.33美元

2026-08-20 19:06

Nova(NVMI) 0
新橋生物(NBP) 0

I-Mab Biopharma press release (NBP): 1H GAAP EPS of -$0.33.
As of June 30, 2026, the company had cash, cash equivalents, short-term investments, and equity investment at fair value of $215.9 million.
Based on its current operating plan, the Company believes its cash position is sufficient to support the advancement of its portfolio through multiple anticipated clinical and strategic milestones, including givastomig’s planned Phase 3 interim data read-out in 2028.

More on I-Mab Biopharma

NovaBridge: Rebranded, Repackaged, But Far From De-Risked
NovaBridge Biosciences appoints Srishti Gupta as CEO
Seeking Alpha’s Quant Rating on I-Mab Biopharma
Historical earnings data for I-Mab Biopharma
Financial information for I-Mab Biopharma

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。